93 related articles for article (PubMed ID: 8637220)
21. Genetic characterization of the multidrug-resistant phenotype of VM-26-resistant human leukemic cells.
Wolverton JS; Danks MK; Schmidt CA; Beck WT
Cancer Res; 1989 May; 49(9):2422-6. PubMed ID: 2539902
[TBL] [Abstract][Full Text] [Related]
22. Nitric oxide-releasing agents and cGMP analogues inhibit murine erythroleukemia cell differentiation and suppress erythroid-specific gene expression: correlation with decreased DNA binding of NF-E2 and altered c-myb mRNA expression.
Suhasini M; Boss GR; Pascual FE; Pilz RB
Cell Growth Differ; 1995 Dec; 6(12):1559-66. PubMed ID: 9019161
[TBL] [Abstract][Full Text] [Related]
23. DNA topoisomerase II alpha gene expression under transcriptional control in etoposide/teniposide-resistant human cancer cells.
Kubo T; Kohno K; Ohga T; Taniguchi K; Kawanami K; Wada M; Kuwano M
Cancer Res; 1995 Sep; 55(17):3860-4. PubMed ID: 7641205
[TBL] [Abstract][Full Text] [Related]
24. Topoisomerase II as a target of VM-26 and 4'-(9-acridinylamino)methanesulfon-m-aniside in atypical multidrug resistant human small cell lung carcinoma cells.
de Jong S; Kooistra AJ; de Vries EG; Mulder NH; Zijlstra JG
Cancer Res; 1993 Mar; 53(5):1064-71. PubMed ID: 8382551
[TBL] [Abstract][Full Text] [Related]
25. Murine erythroleukemia cell differentiation: relationship of globin gene expression and of prolongation of G1 to inducer effects during G1/early S.
Gambari R; Marks PA; Rifkind RA
Proc Natl Acad Sci U S A; 1979 Sep; 76(9):4511-5. PubMed ID: 291983
[TBL] [Abstract][Full Text] [Related]
26. Transcriptional down-regulation of c-myc expression in the MCF-7 breast tumor cell line by the topoisomerase II inhibitor, VM-26.
Orr MS; Fornari FA; Randolph JK; Gewirtz DA
Biochim Biophys Acta; 1995 Jun; 1262(2-3):139-45. PubMed ID: 7599188
[TBL] [Abstract][Full Text] [Related]
27. Potentiation by novobiocin of the cytotoxic activity of etoposide (VP-16) and teniposide (VM-26).
Rappa G; Lorico A; Sartorelli AC
Int J Cancer; 1992 Jul; 51(5):780-7. PubMed ID: 1377186
[TBL] [Abstract][Full Text] [Related]
28. Localisation of DNA topoisomerase IIalpha in mouse erythroleukemia cells.
Ivanova EC; Donev RM; Djondjurov LP
Mol Cells; 1999 Jun; 9(3):309-13. PubMed ID: 10420991
[TBL] [Abstract][Full Text] [Related]
29. A new action for topoisomerase inhibitors.
Zucker RM; Elstein KH
Chem Biol Interact; 1991; 79(1):31-40. PubMed ID: 1647887
[TBL] [Abstract][Full Text] [Related]
30. Single-strand conformational polymorphism analysis of the M(r) 170,000 isozyme of DNA topoisomerase II in human tumor cells.
Danks MK; Warmoth MR; Friche E; Granzen B; Bugg BY; Harker WG; Zwelling LA; Futscher BW; Suttle DP; Beck WT
Cancer Res; 1993 Mar; 53(6):1373-9. PubMed ID: 8383009
[TBL] [Abstract][Full Text] [Related]
31. Multidrug resistance-associated protein gene overexpression and reduced drug sensitivity of topoisomerase II in a human breast carcinoma MCF7 cell line selected for etoposide resistance.
Schneider E; Horton JK; Yang CH; Nakagawa M; Cowan KH
Cancer Res; 1994 Jan; 54(1):152-8. PubMed ID: 7903202
[TBL] [Abstract][Full Text] [Related]
32. Topoisomerase II cleavable complex formation within DNA loop domains.
Lambert JM; Fernandes DJ
Biochem Pharmacol; 2000 Jul; 60(1):101-9. PubMed ID: 10807951
[TBL] [Abstract][Full Text] [Related]
33. DNA topoisomerase II is required for formation of mitotic chromosomes in Chinese hamster ovary cells: studies using the inhibitor 4'-demethylepipodophyllotoxin 9-(4,6-O-thenylidene-beta-D-glucopyranoside).
Charron M; Hancock R
Biochemistry; 1990 Oct; 29(41):9531-7. PubMed ID: 2176848
[TBL] [Abstract][Full Text] [Related]
34. Dissociation between bulk damage to DNA and the antiproliferative activity of teniposide (VM-26) in the MCF-7 breast tumor cell line: evidence for induction of gene-specific damage and alterations in gene expression.
Gewirtz DA; Orr MS; Fornari FA; Randolph JK; Yalowich JC; Ritke MK; Povirk LF; Bunch RT
Cancer Res; 1993 Aug; 53(15):3547-54. PubMed ID: 8339261
[TBL] [Abstract][Full Text] [Related]
35. Differential induction of secondary DNA fragmentation by topoisomerase II inhibitors in human tumor cell lines with amplified c-myc expression.
Bertrand R; Sarang M; Jenkin J; Kerrigan D; Pommier Y
Cancer Res; 1991 Dec; 51(23 Pt 1):6280-5. PubMed ID: 1933888
[TBL] [Abstract][Full Text] [Related]
36. Topoisomerase II cleavage in chromatin.
Udvardy A; Schedl P; Sander M; Hsieh TS
J Mol Biol; 1986 Sep; 191(2):231-46. PubMed ID: 3027349
[TBL] [Abstract][Full Text] [Related]
37. Synthesis of globin mRNA in relation to the cell cycle during induced murine erythroleukemia differentiation.
Gambari R; Terada M; Bank A; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 1978 Aug; 75(8):3801-4. PubMed ID: 278991
[TBL] [Abstract][Full Text] [Related]
38. Suppression of c-myc expression and c-Myc function in response to sustained DNA damage in MCF-7 breast tumor cells.
Magnet KJ; Orr MS; Cleveland JL; Rodriguez-Galindo C; Yang H; Yang C; Di YM; Jain PT; Gewirtz DA
Biochem Pharmacol; 2001 Sep; 62(5):593-602. PubMed ID: 11585056
[TBL] [Abstract][Full Text] [Related]
39. Changes in gene expression associated with induced differentiation of erythroleukemia: protooncogenes, globin genes, and cell division.
Ramsay RG; Ikeda K; Rifkind RA; Marks PA
Proc Natl Acad Sci U S A; 1986 Sep; 83(18):6849-53. PubMed ID: 3462732
[TBL] [Abstract][Full Text] [Related]
40. Erythroid potentiating activity of tissue inhibitor of metalloproteinases on the differentiation of erythropoietin-responsive mouse erythroleukemia cell line, ELM-I-1-3, is closely related to its cell growth potentiating activity.
Murate T; Yamashita K; Ohashi H; Kagami Y; Tsushita K; Kinoshita T; Hotta T; Saito H; Yoshida S; Mori KJ
Exp Hematol; 1993 Jan; 21(1):169-76. PubMed ID: 8417953
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
